Core Insights - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. regarding alleged violations of federal securities laws related to misleading statements about the Inspire V device launch [3][6] - Investors who suffered losses from August 6, 2024, to August 4, 2025, are encouraged to contact the firm to discuss their legal options before the January 5, 2026, deadline for seeking lead plaintiff status in a federal securities class action [2][3] Company Performance - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays due to incomplete training and onboarding at treatment centers [7] - The company faced billing and reimbursement challenges, with necessary software updates for claims processing not effective until July 1, 2025, leading to continued use of the older Inspire IV system [7] - Demand for the Inspire V device was reported as weak, resulting in excess inventory and a drastic cut in 2025 earnings guidance by over 80% [8] Market Impact - Following the announcement of these issues, Inspire Medical's stock price plummeted by more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, erasing approximately $1.2 billion in market capitalization [8]

Core Insights - Stride, Inc. is facing legal scrutiny following allegations of fraud and deceptive practices related to inflated enrollment numbers and compliance violations [5][6] - The company's stock has experienced significant declines, with a drop of 11.7% on September 15, 2025, and a further decline of up to 51% during intraday trading on October 29, 2025, following the release of disappointing financial results [6][7] Legal Issues - The Gallup-McKinley County Schools Board of Education has filed a complaint against Stride, alleging systemic violations of law and intentional misconduct [5] - The allegations include retaining "ghost students" to secure state funding and ignoring compliance requirements for employees [5] Financial Performance - In its first quarter fiscal 2026 results, Stride reported a deliberate limitation on enrollment growth due to operational issues, resulting in 10,000 to 15,000 fewer enrollments [7] - The company acknowledged "system implantation issues" that led to higher withdrawal rates and lower conversion rates, which are expected to restrict in-year enrollment growth [7]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated related to misleading statements about the New Drug Application (NDA) for aficamten, with a lead plaintiff deadline of November 17, 2025 [2][5]. Group 1: Legal Investigation - The law firm is reminding investors of the upcoming deadline to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [2]. - Investors who acquired Cytokinetics securities between December 27, 2023, and May 6, 2025, are encouraged to discuss their legal rights [1][2]. Group 2: Allegations Against Cytokinetics - The complaint alleges that Cytokinetics made materially false and misleading statements regarding the NDA submission timeline and approval process for aficamten, claiming expected FDA approval in the second half of 2025 [5]. - It was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [6]. Group 3: Impact on Investors - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and suffered significant losses when the truth was disclosed [7]. - The lead plaintiff in the class action will be the investor with the largest financial interest who can adequately represent the class [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][5]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - Specific allegations include a dislocation between premium rates and medical costs, dependence on low utilization of various health services for near-term growth, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [6][7]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50, leading to a stock price drop of $6.97, or 2.9%, to close at $232.61 [7]. - On July 23, 2025, Molina further slashed its full-year 2025 earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% year-over-year decrease, and cutting its full-year adjusted earnings guidance to no less than $19.00 per diluted share, resulting in a stock price decline of $32.03, or 16.84%, to close at $158.22 [8]. Group 3: Legal Proceedings and Investor Actions - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9]. - Faruqi & Faruqi encourages anyone with information regarding Molina's conduct to contact the firm, including whistleblowers and former employees [10].

New York, New York--(Newsfile Corp. - November 11, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Molina Healthcare, Inc. ("Molina Healthcare, Inc.") (NYSE: MOH) concerning possible violations of federal securities laws.On October 23, 2025, Molina published its third quarter, fiscal 2025 earnings well below consensus and slashed its guidance for the third time this year, citing cost pressure and underperformance. The Company is now expecting earnings of $14 per share ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Wildermuth Fund due to allegations of violations of federal securities laws, encouraging affected investors to discuss their legal options [2][5]. Group 1: Legal Investigation and Claims - The firm is urging investors who suffered losses in the Wildermuth Fund between November 1, 2020, and June 29, 2023, to contact them for legal discussions [1]. - A federal securities class action has been filed against Wildermuth Fund, with a deadline of December 29, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that the Fund and its executives made false or misleading statements and failed to disclose critical information regarding the Fund's investments [5]. Group 2: Fund Performance and Management Changes - On June 29, 2023, the Fund's Board approved a liquidation plan based on the adviser's recommendation, despite reassurances about the underlying investments [6]. - Daniel and Carol Wildermuth resigned from their positions on November 1, 2023, and the agreement with the previous adviser was terminated, with BW Asset Management Ltd. appointed as the new investment adviser [7]. - By October 2024, the value of the Fund's investments had decreased by 63.6% compared to March 2022, and the net asset value (NAV) had declined by 73.7% [8].

Core Points - Levi & Korsinsky has initiated an investigation into Beyond Meat, Inc. for potential violations of federal securities laws [1] - Beyond Meat announced an expected non-cash impairment charge for the three months ending September 27, 2025, related to certain long-lived assets, which is anticipated to be material [1] - Following the announcement, Beyond Meat's stock price dropped over 23% on October 24, 2025 [1] Company Overview - Beyond Meat, Inc. is facing scrutiny due to its recent financial disclosures and the subsequent impact on its stock performance [1] - The investigation by Levi & Korsinsky highlights the firm's focus on protecting shareholder interests in cases of potential securities law violations [2]

Core Viewpoint - Berman Tabacco is investigating potential stockholder claims against Live Nation Entertainment, Inc. for allegedly deceiving consumers and violating federal law [1] Investigation Details - The Federal Trade Commission (FTC) and seven states filed a civil complaint against Live Nation and Ticketmaster, alleging systematic violations of federal law that generated hundreds of millions in revenue through deceptive practices [2] - The complaint highlights a specific incident where a broker used multiple accounts to purchase 9,000 tickets for a Beyonce concert, reselling 2,500 tickets at inflated prices, resulting in additional fees for Live Nation and Ticketmaster [2] Management Involvement - Allegations suggest that senior officers of Live Nation and Ticketmaster were complicit in the deception, instructing management to ignore ticket brokers bypassing enforcement measures [3] - Following the FTC's complaint, Live Nation's shares experienced a decline of approximately 3% [3] Board Investigation - Berman Tabacco is examining whether the board of directors of Live Nation played a role in the alleged scheme and if there were breaches of fiduciary duties by its officers and/or directors [4]

Core Insights - Molina Healthcare, Inc. is under investigation for possible violations of federal securities laws following disappointing earnings and guidance cuts [1][2] - The company reported third quarter fiscal 2025 earnings significantly below consensus, with an expected full-year earnings of $14 per share, down from a previous estimate of "no less than $19" [2] - Molina's stock price dropped by $38.08 to open at $157.05 per share after the earnings announcement [3] Financial Performance - Molina's third quarter earnings were well below market expectations, primarily due to cost pressures and underperformance in its marketplace business [2] - The company has revised its earnings guidance for the third time in 2025, indicating ongoing financial challenges [2] Stock Market Reaction - Following the earnings report, Molina's stock experienced a significant decline, reflecting investor concerns over the company's financial outlook [3]

Core Points - Berman Tabacco is investigating potential stockholder claims against SelectQuote, Inc. regarding allegations of illegal payments from health insurance providers [1] - Allegations suggest that SelectQuote received illegal payments exceeding 80 million dollars from Humana and Aetna between 2016 and 2021 to direct customers towards their Medicare offerings [2] - The investigation will examine the involvement of SelectQuote's board of directors and whether there were breaches of fiduciary duties by its officers and/or directors [3] Investigation Details - The allegations were unsealed in May 2025 after the U.S. Attorney's Office for the District of Massachusetts intervened, joining claims initially raised by a whistleblower [2] - Following the filing of the Department of Justice's complaint, SelectQuote's shares declined approximately 20% [2]